Scilex Holding (SCLX) Research & Development (2022 - 2026)
Scilex Holding (SCLX) posted Research & Development of $3.3 million for Q2 2026, up 3.93% on a QoQ basis from $3.2 million in Q1 2026, and down 46.08% year-over-year from $6.2 million in Q2 2025.
Analysis
Scilex Holding (SCLX) Research & Development (2022 - 2026) Analysis & Trends
Scilex Holding has reported Research & Development for 5 years, with the latest figure at $3.3 million in Q2 2026.
- On a quarterly basis, Research & Development fell 46.08% year-over-year to $3.3 million in Q2 2026; TTM through Jun 2026 was $18.6 million, a 41.31% increase from a year earlier, with the FY2025 full-year figure at $20.7 million, up 114.81% from the prior year.
- Research & Development was $3.3 million for Q2 2026 at Scilex Holding, up from $3.2 million in the prior quarter.
- The five-year high for Research & Development was $8.2 million in Q4 2025, with the low at $1.2 million in Q3 2022.
- Average Research & Development over 5 years is $3.3 million, with a median of $2.7 million recorded in 2023.
- The sharpest annual moves came in 2025 and 2026: Research & Development surged 274.68% in 2025, then sank 46.08% in 2026.
- Over 5 years, Research & Development stood at $2.6 million in 2022, then increased by 5.28% to $2.7 million in 2023, then declined by 20.26% to $2.2 million in 2024, then soared by 274.68% to $8.2 million in 2025, then sank by 59.16% to $3.3 million in 2026.
- The last three Research & Development figures came in at $3.3 million (Q2 2026), $3.2 million (Q1 2026), and $8.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.81 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -2.60 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 394.92 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 516.95 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 146.30 Mn |
| 10 | Scilex Holding | 35.91 Mn | -76.88 Mn | 3.97 Mn | 3.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.34 Mn |
| Mar 31, 2026 | 3.21 Mn |
| Dec 31, 2025 | 8.17 Mn |
| Sep 30, 2025 | 3.90 Mn |
| Jun 30, 2025 | 6.19 Mn |
| Mar 31, 2025 | 2.46 Mn |
| Dec 31, 2024 | 2.18 Mn |
| Sep 30, 2024 | 2.35 Mn |
| Jun 30, 2024 | 2.00 Mn |
| Mar 31, 2024 | 3.11 Mn |
| Dec 31, 2023 | 2.73 Mn |
| Sep 30, 2023 | 4.07 Mn |
| Jun 30, 2023 | 3.20 Mn |
| Mar 31, 2023 | 2.74 Mn |
| Dec 31, 2022 | 2.60 Mn |
| Sep 30, 2022 | 1.24 Mn |
| Jun 30, 2022 | 2.59 Mn |
| Mar 31, 2022 | 2.63 Mn |